NICE draft rejects Sanofi-Aventis's Multaq, but U-turns on Yondelis
This article was originally published in Scrip
Executive Summary
The UK's National Institute for Health and Clinical Excellence (NICE) has rejected the NHS use (in England and Wales) of Sanofi-Aventis's atrial fibrillation (AF) treatment, dronedarone (Multaq), in the first appraisal draft of the anti-arrhythmic drug.